Sermorelin.com Introduces Physician-Led Telehealth for Sermorelin Treatment
Sheridan, United States – March 15, 2026 / Sermorelin.com /
Sermorelin.com has officially launched a new telehealth platform dedicated to sermorelin therapy, responding to the growing interest among clinicians in combining sermorelin with GLP-1 protocols. This innovative platform connects patients with licensed healthcare providers who can offer sermorelin treatment under proper medical supervision. The launch comes at a time when research, including a 2025 PMC case series, has shown promising results in fat loss while preserving lean tissue, further fueling interest in sermorelin as a viable treatment option.
Mark Lombardi, CEO of Sermorelin.com, stated, “Our goal is to create a dedicated platform for sermorelin under proper medical supervision. Meaningful early research exists on combining sermorelin with GLP-1, and we believe this combination can enhance patient outcomes.” The platform aims to provide a safe and effective way for patients to access sermorelin therapy, ensuring that they receive the necessary guidance and support from qualified professionals.
Sermorelin is a 29-amino acid fragment of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to produce and release growth hormone (GH), which plays a crucial role in various bodily functions, including metabolism, muscle growth, and overall health. One of the significant advantages of sermorelin is that it retains eligibility for 503A compounding, allowing for personalized treatment options tailored to individual patient needs.
Research has shown that sermorelin can lead to significant improvements in body composition. A study published in the Journal of Clinical Endocrinology & Metabolism (JCEM) reported an average lean mass gain of 1.26 kg among participants undergoing sermorelin treatment. Additionally, a meta-analysis published in the Annals of Internal Medicine found an average gain of 2.1 kg in lean mass, further supporting the efficacy of sermorelin in promoting muscle growth while aiding in fat loss.
As with any medical treatment, it is essential to consider potential side effects. Common side effects associated with sermorelin treatment include injection site reactions, headaches, flushing, and nausea. It is important to note that the FDA has not withdrawn sermorelin from the market for safety reasons since its approval in 2013, indicating that it remains a safe option for patients when used under medical supervision.
In closing, Mark Lombardi emphasized the importance of sermorelin in the realm of hormone optimization, stating, “Sermorelin is one of the most important tools in hormone optimization.” The launch of the telehealth platform by Sermorelin.com represents a significant step forward in making this valuable treatment more accessible to patients seeking to improve their health and well-being.
Sermorelin.com is the only platform dedicated exclusively to sermorelin peptides, offering physician-directed telehealth services. This unique focus allows the company to provide specialized care and support for patients interested in sermorelin therapy, ensuring they receive the highest quality of medical attention.
It is important to note that the information provided by Sermorelin.com is not intended as medical advice. Patients seeking sermorelin treatment must obtain a prescription from a licensed healthcare provider. Additionally, while sermorelin has shown promise in various studies, it is not FDA-approved for all uses, and patients should discuss their options with their healthcare provider to determine the best course of action for their individual needs.
Learn more on https://sermorelin.com/
Contact Information:
Sermorelin.com
30 N Gould St Ste R
Sheridan, WY 82801
United States
Mark Lombardi
+1 307-217-6473
https://sermorelin.com
